Last update :
28/04/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Various   Filgrastim  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Accofil Belgium, Germany, Great Britain
Biocilin Mexico
Duperan Chile
Filgen Argentina
Foltran Chile
Granulokine Greece, Italy
Hebervital Colombia
Inmunef Colombia
Leucosos Colombia
Lioplim Chile
Neupogen Austria, Belgium, Croatia, Denmark, Finland, France, Great Britain, Netherlands, Poland, Portugal, Republic of South Africa, Slovenia, Spain, Sweden, Switzerland, Turkey, United States of America
Neutromax Argentina
Neutropine Argentina
Nivestim Belgium, France, Germany, Great Britain, Netherlands, Norway
Ratiograstim Austria, Germany, Great Britain, Sweden
Tevagrastim Germany, Great Britain, Netherlands, Norway, Sweden, Switzerland
References   Injection   References : Filgrastim  
Type Publication
99 Journal Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104 Journal Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189.
182 Journal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Journal Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
2269 Journal Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3128 Manufacturer Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3249 Journal Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3256 Journal Burnett B, Radic I.
Stability of Hospira filgrastim following changes to thermal and photic storage conditions.
EJHP 2011 ; 17, 5: 49-56.
3474 Manufacturer Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3618 Manufacturer Filgrastim (Neupogen®) - Summary of Product Characteristics
Amgen 2014
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 Journal Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4380 Manufacturer Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4471 Manufacturer Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019
4521 Journal Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
4650 Manufacturer Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
  Mentions Légales